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Holocarboxylase synthetase (HCS) catalyzes the binding of biotin to lysine (K)
residues in histones H3 and H4. Histone biotinylation marks play important roles in the
repression of genes and retrotransposons. Preliminary studies suggest that K16 in histone
H4 is a target for biotinylation by HCS. Here we tested the hypothesis that H4K16bio is a
real histone mark in human chromatin, and that H4K16bio is overrepresented in
repressed gene loci and repeat regions. Polyclonal rabbit anti-human H4K16bio was
generated

and

affinity

purified.

Using

anti-H4K16bio

and

chromatin

immunoprecipitation assays, we demonstrated that H4K16bio is overrepresented in repeat
regions (pericentromeric alpha satellite repeats; long terminal repeats (LTR) compared
with euchromatin promoters. H4K16bio was also enriched in the repressed interleukin-2
gene promoter. The enrichment at LTR22 and promoter 1 of the sodium-dependent
multivitamin transporter (SMVT) depended on biotin supply; the enrichment was greater
in biotin-supplemented cells compared with biotin-normal and biotin-deficient cells. The

enrichment of H4K16bio at LTR15 and SMVT promoter 1 was significantly lower in
fibroblasts from an HCS-deficient patient compared with an HCS wild-type control. We
conclude that H4K16bio is a real phenomenon and that this mark, like other biotinylation
marks, plays a role in the transcriptional repression of repeats and genes.
HCS catalyzes the covalent binding of biotin to carboxylases, in addition to its role
as a histone biotinyl ligase. Biotinylated carboxylases play crucial roles in the
metabolism of fatty acids, amino acids, and glucose. HCS null individuals are not viable
whereas HCS deficiency is linked to developmental delays and phenotypes such as short
life span and low stress resistance. Here, we developed a 96-well plate assay for highthroughput analysis of HCS based on the detection of biotinylated p67 using IRDyestreptavidin and infrared spectroscopy. We demonstrated that the catalytic activity of
rHCS depends on temperature and time, and proposed optimal substrate and enzyme
concentrations to ensure ideal measurement of rHCS activity and its kinetics.
Additionally, we demonstrated that this assay is sensitive enough to detect biotinylation
of p67 by endogenous HCS from Jurkat lymphoid cells.
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6
Biotin

Biotin, also known as vitamin B7 or H, is a water-soluble vitamin involved in many
metabolic pathways in mammals (1). Chemically, biotin is a monocarboxylic acid
consisting of a ureido group, thiophane heterocyclic ring, and a valeric acid side chain
(1-3) (Fig. 1).

Figure 1. Biotin structure

Humans cannot synthesize biotin but depend on dietary biotin supply (4). Biotin can
be found in high concentration in egg yolk, cow milk, liver and some vegetables (5). For
absorption of dietary biotin, the protein-bound biotin in foods has to be converted to free
biotin by the action of gastrointestinal proteases, peptidases, and biotinidase (1, 5). The
uptake of free biotin by the cells is mediated by the sodium-dependent multi-vitamin
transporter (SMVT) which also transports

pantothenic acid and lipoate (5, 6).

Monocarboxylate transporter 1 (MCT1) has also been reported to participate in the
transport of biotin, but its function is restricted to lymphoid cells (7, 8) (Fig. 2).
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Figure 2. Biotin transport and metabolism, modified from (9). B: biotin, SMVT:
sodium multivitamin transporter, MCTI: monocarboxylate transporter 1, PCC: propionylCoA carboxylase,
ACC1: cytoplasmatic acetyl-CoA carboxylase α, ACC2:
mitochondrial acetyl-CoA carboxylase β, PC: pyruvate carboxylase, MCC: and 3methylcrotonyl-CoA carboxylase.

Biotin plays important roles in the metabolism of glucose, amino acids and fatty
acids due to its role as a coenzyme in the metabolism of propionyl-CoA carboxylase
(PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial acetyl-CoA
carboxylase

2 (ACC2), pyruvate carboxylase (PC) and 3-methylcrotonyl-CoA

carboxylase (MCC) (10, 11). Additionally, it has been shown that biotin is involved in
gene regulation by its attachment to histones in the chromatin (10).
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Holocarboxylase Synthetase (HCS)

HCS functions as a biotin-ligase for carboxylases and histones (Fig. 3). This enzyme
is a 726 amino acid protein with an estimate molecular weight of 81 kDa (12). Four
domains in human HCS have been identified: the N-terminal domain, C-terminal domain,
central domain, and linker domain (13) (Fig-3). The N-terminal and C-terminal domains
have been proposed to participate in substrate recognition while central domain has the
binding sites for ATP and biotin (13). The linker domain has been associated with the
flexibility of HCS to interact with other substrates for biotinylation (13). It has been
reported that HCS localizes in mitochondria and cell nuclei; however due to HCS lacks
of nuclear localization sequence and DNA binding motif (14) its localization in the
nucleus is still controversial (15, 16).

Figure 3. Four domains in human HCS: N-terminal domain, central domain (CD)
containing biotin and ATP binding sites, linker domain (L), and C-terminal domain (CT)
(13).
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HCS catalyzes biotinylation of carboxylases and histones in a two-step ATPdependent reaction (17). In the first step, biotinyl 5’-AMP (B-AMP) is generated; in the
second step, biotin is transferred from B-AMP to the lysine residue in the
apocarboxylases and histones (15). It has been demostrated that HCS acts as its ortholog
BirA ligase found in Escherichia coli. BirA ligase participates in the biotinylation of
biotinoyl carboxyl carrier protein (BCCP) and its amino acid sequence is 21% identical
with HCS (18-21).
The important role of HCS in biotinylation of histones has been confirmed in
various studies (22, 23). Camporeale et al. compared the ability of SMVT mutants and
HCS-deficient Drosophila melanogaster

to biotinylate histones.

The results

demonstrated that HCS knockdown is associated with a decrease in biotinylation of
histones due to the low biotin-ligase activity, rather than the low levels of biotin in the
cells (22). Importantly, Baolong et al. recently reported that HCS interacts physically
with histone H3 to mediate binding to chromatin and subsequent biotinylation of K9 and
K18 in histone H3 (24).
For the study of the activity of HCS, a peptide spanning C-terminal 67 amino acids
of PCC, known as p67, has been used as substrate for biotinylation by HCS in previous
studies (25-27). p67 contains the biotin-binding consensus sequence (AMKM) for biotin
binding (26, 27). In this thesis p67 was used as a substrate for the development of the 96well plate assay for high-throughput screening of HCS activity (see Chapter 3).
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Biotinidase (BTD)
BTD belongs to the nitrilase superfamily of enzymes which consists of 12 families
of amidases, N-acyltransferases, and nitrilases (28). BTD shares significant sequence
similarities with some members of the nitrilase superfamily such as vanins -1, -2 and -3
(29). In mammalian cells, 26% of the cellular biotinidase activity resides in the nucleus
(30) although its nuclear localization has been disputed subsequently (31). The BTD
gene localizes in chromosome 3p25 and its structure has been determined (32). The BTD
gene contains four exons: A125-44, B45-309, C310-459 and D460-1961. Exons B through D
code for the mature protein (31) while the 5’-flanking region of exon 1 contains a
CCAAT element, three initiator sequences, an octamer sequence, three methylation
consensus sites, two GC boxes, and one HNF-5 site but lacks a TATA element (32).
The classical role of BTD in metabolism is to hydrolyze biocytin (biotinyl- ε -lysine)
generated in the breakdown of biotin-dependent carboxylases (33). Thus, free biotin is
released and recycled in holocarboxylase synthesis and used in other processes (10). The
role of BDT in biotinylation of histones has been demonstrated based on in vitro studies
with purified histones (33). It was proposed that BTD might mediate the binding of
biotin to histones by the hydrolysis of biocytin forming a biotinyl-thioester intermediate
(cysteine-bound biotin) near its active site. Thus, biotin is bound to the biotinyl moiety
from the cysteine residue and transfer to the ε-amino group of the lysine in histones (20,
33).
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Evidence has been provided that BTD might catalyze debiotinylation of histones
(34). It was proposed that variables such as microenviroment in chromatin,
posttranscriptional modifications and alternative splicing might determine whether BTD
acts as a biotinyl histone transferase or histone debiotinylase (1). For example covalent
modifications such as glycosylation might influence the enzyme activity to biotinylate or
debiotinylate histones (34, 35). In the same way, the presence of cofactors such as high
concentrations of biocytin might favor and increase the rate of biotinylation of histones
(34).

Apocarboxylases
Biotin serves as a covalently bound coenzyme for propionyl-CoA carboxylase
(PCC), cytoplasmatic acetyl-CoA carboxylase 1 (ACC1), mitochondrial acetyl-CoA
carboxylase 2 (ACC2), pyruvate carboxylase and 3-methylcrotonyl-CoA carboxylase
(MCC) (10, 11). Biotin is covalently attached to the ε-amino group of a distinct lysine
residue in holocarboxylases (inactive enzyme) by holocarboxylase synthetase (HCS) (15,
25, 36).
In the cell, PCC localizes in the mitochondria and is required for catabolism of the
amino acids isoleucine, threonine, methionine, valine, and odd chain fatty acids (10). It
is also involved in the carboxylation of propionyl-CoA to D-methylhalonyl-CoA (37, 38).
The last 67 amino acids of PCC C-terminus domain has been used as an important tool
for study of the bioactivity of HCS because its properties as a well-established HCS
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substrate (25, 26). This polypeptide, known as p67, contains the biotin-binding consensus
(AMKM) sequence (26, 27).
ACC1 and ACC2 catalyze the binding of bicarbonate to acetyl CoA, generating
malonyl CoA (10). These two enzymes share approximately 70% of the amino acid
sequence but differ in cellular localization (10, 39, 40). ACC1 participates in fatty acid
synthesis in cytoplasm, while ACC2 participates in the regulation of fatty acid oxidation
in mitochondria (10).
PC participates in the carboxylation of pyruvate to oxalacetate in gluconeogenesis
(10, 41), and

MCC participates in the catabolism of the leucine by converting 3-

methylcrotonyl-CoA to 3-methylglutaconyl-CoA (42).

Biotin and Gene expression

Interleukin-2
Human lymphoid cells normally secret cytokines in response to stimulation of the
immune system (43, 44). Interleukin-2 (IL-2) is a cytokine secreted when a cell surface
receptor interacts with its specific ligand molecule causing a rapid hydrolysis of inositol
phospholipids to diacylglicerol and inositol phosphates by phospholipase C (PLC) (43,
44). Diacylglycerol then activates protein kinase C (PKC) and inositol phosphate, thus,
triggering the release and mobilization of Ca++.

This process results in additional
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cellular responses that mediate T-cell activation, and therefore IL-2 production and
secretion (43, 44).
In vitro, phorbol 12-myristate 13-acetate (PMA) has been used to stimulate
production of IL-2. PMA has an analogous structure to diacylglycerol, thus, it activates
PKC and T-cells to stimulate IL-2 production. A combination of PMA with
phytohemaglutinin (PHA), a co-stimulator that binds non-specifically to the cell surface
receptor complex, can be used to increase IL-2 expression (43, 44).
Previous studies have provided evidence that biotin plays an important role in
immune function (45-50). For instance, biotin supplementation has been reported to
decrease the secretion of interleukin-2 and interleukin-1β by PBMC (51). In addition,
the association of biotin with repression of the gene coding for IL-2 (52, 53) was
reported by Camporeale at el when they demonstrated that biotinylation of K12 in
histone H4 represses interleukin-2 gene (52). Likewise, Pestinger at el, reported similar
observations with the biomarks H3K9bio, H3K18bio and H4K8bio (53).

Transposable elements: Long terminal repeats (LTR)
Transposable elements are sequences in the DNA that can change their positions
within the genome of a single cell in a process called transposition (54-56). Transposition
has been associated with mutations and abnormal patterns in gene expression (57, 58). In
mammals, transposable elements type I constitute approximately 42% of the human
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genome and are divided into two groups: the long terminal repeats (LTR) and the long
interspersed nucleotide elements (LINE) (59). Additionally, LTRs are grouped in intact
retrotransposons LTR and solitary LTR (59). In the intact retrotransposons LTR, the
viral genes gag, pol and enw are flanked by two repeat regions: 5’-LTR and 3’-LTR, and
the expression of retroviral genes is regulated by 5’-LTR (59, 60). In the case of solitary
LTR, the retroviral genes have been deleted by recombination of the LTR ; (54, 57-60),
and therefore they are unable to produce viral proteins. However, they may have
retained their promoter activity; which could cause abnormal patterns of

host gene

expression (57, 58).
Previous studies have suggested that biotinylation plays an important role in the
silencing of genes coding for retrotransposons (59). It was found, that biotinylation of
lysine 12 in histone H4 (H4K12bio) and lysine 9 in histone H2 (H2AK9bio) represses
retrotransposon transcription in human and mouse cell lines (59). Additionally,
biotinylation of lysines 9 and 18 in histone H3 (H3K9bio and H3K18bio), and lysine 8
in histone H4 (H4K8bio) were associated with LTR repression in human lymphoid cells
(53).
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Biotin Deficiency

Symptoms of biotin deficiency can be found in individuals with insufficient dietary
intake; mutations in BTD, HCS, SMVT or carboxylases (10), and in individuals that
consume large amounts of raw egg white, lipoic acid, excessive alcohol, or are on termlong drugs treatments (10, 61, 62).

Symptoms can go from

feeding difficulties,

hypotonia, vomiting, alopecia, ataxia, conjunctivitis, periorifitial dermatitis and skin
infections to critical progressive loss of consciousness, coma and death (12, 62, 63). Its
diagnosis is suggested by the increase in the excretion of organic acids such as lactate
and

3-hydroxyisovaleric acid in the urine,

and its treatment consists in

the

administration of pharmacological oral doses of biotin (15).
Mutations in HCS lead to the inability to form active holocarboxylases resulting in
multiple carboxylases deficiency (MCD) (10, 62); while the defects of BTD has effects
in the recycling of biotin from degraded carboxylases and the release of biotin from
dietary proteins (10). Importantly, previous studies suggested that half of the pregnant
women in USA experience marginal biotin deficiency (64-68); however, its impact as
teratogenic effect has not been demonstrated in humans. On the contrary, studies with
mice showed fetal malformations such as cleft palate and micromelia (69, 70).
Studies with Drosophila melanogaster suggest that biotin deficiency caused by
mutant HCS resulted in a decrease of life span (up to 32%) and stress survival (22, 71).
Moreover, it was demonstrated that these effects were caused by the deficiency of histone
biotinylation rather than carboxylases. In addition, it was proposed that HCS deficiency
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affected gene expression in these cells due to chromatin modifications. The results
showed a 50% decrease in the expression of 77 genes associated with defense response,
and a 100% increase of 124 genes involved in signal transduction, transport and cell
death (22, 71).

Histones and Chromatin
Histones are small basic proteins (11-22 kDa) involved in the folding of the DNA
into chromatin (72). They are modified by the covalently binding of biotin to lysine
residues by holocarboxylase synthetase (73, 74). There are five major classes of histones
in chromatin: H1, H2A, H2B, H3 and H4 (74). Histones H2A, H2B, H3 and H4 form an
octamer of core histones with one H3-H3-H4-H4 tetramer and two H2A-H2B dimers
while histone H1 is the linker histone bound to the DNA in between two nucleosomes
(Fig. 4) (75). Importantly, histones are positively charged proteins due to the presence of
a large number of lysine and arginine residues (20-25% of the amino acids).

The

electrostatic interaction between the negative charge of DNA and the positive charge of
histones stabilizes the formation of the nucleosomal core particle (74).

17

Figure 4. Nucleosome structure. Octamer of histones.
http://www.statemaster.com/encyclopedia/Nucleosome

Covalent histones modifications
Histones are target for reversible covalent modifications such as acetylation,
methylation, phosporylation, poly (ADP-ribosylation) and biotinylation. These
modifications have distinct functions in gene expression, chromatin remodeling,
transcriptional regulation, and DNA repair (15, 76-78). For example, acetylation of lysine
residues has been associated with transcriptional activity of genes (79). Acetylation
neutralizes the charges of lysine residues allowing dissociation of histones from DNA.
This dissociation allows RNA polymerase to access the promoter region and begin
transcription (79). In contrast, hypoacetylation has been associated with repression (79).
Methylation, may be associated with transcriptional activation or repression. For
instance, methylation of K9 in histone H3 is associated with heterochromatin (inactive
genes), whereas

methylation of Lys K4 in histone H3 is associated with active
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transcription (80). Phosphorylation and poly (ADP-ribosylation) are associated with
signaling and DNA repair (81).
Biotinylation of Histones
In previous studies, 11 biotinylation sites in histones have been identified: K9, K13,
K125, K127 and K129 in histone H2A (82); K4, K9, K18 and perhaps K23 in histone H3
(72); and K8 and K12 in histone H4 (83) (Fig. 5).
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Figure 5. Covalent modifications in human histones,
modified from (2).
Abbreviations: A: acetate, B: biotin, M: methyl, P: phosphate, U: ubiquitin.
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Biotinylation of histones plays an important role in the cellular response to DNA
damage (84), cell proliferation (73), and mitotic condensation of chromatin (85). In fact,
H4K12bio has been associated with gene silencing (52) and repression of transponsable
elements (86).
The use of specific antibodies for studies of histone biotinylation has become an
important tool for studying their biological functions (82, 83, 87, 88). In previous studies
specific antibodies to H4K12bio were generated to investigate its relative enrichment in
repeat regions such as pericentromeric alpha satellite repeats (52) and telomeres (89) , as
well as

its association

with the repression of SMVT transporter gene and

retrotransponsons (59, 90). Pestinger et al. also used specific antibodies to report the
enrichment of H3K9bio, H3K18bio and H4K8bio in pericentromeric alpha satellite
repeats, long terminal repeats, and promoter 1 of the SMVT gene (53). The biological
functions of the other biotinylation sites are still unknown. Mass spectrometry studies
provided preliminary evidence for the existence of a novel biotinylation site, H4K16bio,
in addition to the 11 known biotinylation sites, but with inconclusive results (87).
This master thesis focused on two major projects. First, I discovered a new histone
biotinylation site, K16-biotinylated histone H4, and generated first insights into its
biological functions in gene regulation and chromatin structure (see chapter 2). Second, I
developed a 96 well-plate assay for high-throughput screening of HCS (see chapter 3).
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CHAPTER 2

K16-BIOTINYLATED HISTONE H4 IS OVERREPRESENTED IN
REPEAT REGIONS AND PARTICIPATES IN THE REPRESSION
OF TRANSCRIPTIONALLY COMPETENT GENES IN HUMAN
JURKAT LYMPHOID CELLS
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Introduction

Histones mediate the folding of DNA into chromatin (1). Amino acid residues in the
N-terminal tails and, to a lesser extent, other domains of histones are targets for covalent
modifications such as acetylation and methylation (2). These posttranscriptional
modifications play important roles in gene regulation, chromatin remodeling, mitosis, and
DNA repair. For example, lysine (K)-9 acetylated histone H3 (H3K9ac) and K4trimethylated histone H3 (H3K4me3) are overrepresented in transcriptionally active
euchromatin, whereas hypoacetylated histones and K9-dimethylated histone H3
(H3K9me2) are overrepresented in heterochromatin and repressed genes.
Wolf and co-workers provided evidence that histones are also modified by covalent
attachment of the vitamin biotin, based on in vitro studies with purified histones and the
histone biotinyl ligase, biotinidase (3). Subsequently, biotinylated histones were detected
in chromatin from human and other metazoans by using radiotracers, streptavidin, antibiotin, biotinylation site-specific antibodies, and mass spectrometry {(4-9), T. Kuroishi et
al., unpublished}. The majority of biotinylation takes place at K4, K9, K18, and perhaps
K23 in histone H3 (10, 11), and K8 and K12 in histone H4 (6), but a weak biotinylation
signal can also be detected in histone H2A (4, 12). These previous studies also suggest
that holocarboxylase synthetase (HCS) is more important than biotinidase for catalyzing
biotinylation of histones in vivo (7, 11, 13). Phenotypes of HCS knockdown include a
short life span and low heat survival in Drosophila melanogaster (7) and aberrant gene
regulation in humans (14, 15).
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Biotinylation of histones is a fairly rare event, i.e., less than 0.1% of histones in bulk
extracts are biotinylated in samples of human origin {(16), T. Kuroishi et al.,
unpublished}. However, the comparably low level of global histone biotinylation is not
representative of the level of biotinylation in confined regions of chromatin. For example,
about one of three histone H4 molecules in telomeric repeats is biotinylated at K12 (17).
Biotinylation of histones has important functions in gene repression and genome stability.
Previous studies suggest that K9- and K18-biotinylated histone H3 (H3K9bio,
H3K18bio) and K8- and K12-biotinylated histone H4 (H4K8bio, H4K12bio) are enriched
in repeat regions and participate in gene repression (14, 15, 17-19). The abundance of
histone biotinylation marks depends on both biotin supply and HCS activity (14, 15, 19);
low abundance of H4K12bio in biotin- or HCS-deficient humans, mice, and flies derepresses retrotransposable elements, thereby increasing genome instability and possibly
cancer risk (14).
Preliminary mass spectrometry studies provided evidence that histone H4 is also
biotinylated at K16 (H4K16bio) (12). Here, we tested the hypotheses that H4K16 is a true
biotinylation mark in human chromatin and that H4K16bio, like other biotinylation
signatures, is overrepresented in repeat regions and participates in the repression of
transcriptionally competent chromatin.
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Materials and Methods

Cell culture:

Jurkat human lymphoma cells (ATCC, Manassas, VA) were cultured in commercial
RPMI-1640 (Thermo Scientific, Waltham, MA) using standard cell culture techniques
(20). Regular commercial RPMI-1640 contains 820 nmol/l biotin, which is >3,000 times
the biotin concentration in human plasma (21). In some experiments, cells were cultured
in biotin-deficient (0.025 nmol/l biotin), biotin-physiological (0.25 nmol/l biotin), and
biotin- pharmacological (10 nmol/l biotin) media for 12 d prior to analysis (20). These
concentrations represent levels observed in plasma from biotin-deficient individuals,
biotin-normal individuals, and individuals taking over-the-counter biotin supplements
(21, 22). Biotin-defined media were prepared using customized RPMI-1640 and biotindepleted fetal bovine serum (20). Efficacy of treatment was confirmed by probing
biotinylated carboxylases with IRDye-streptavidin (19). Where indicated, expression of
interleukin-2 (IL-2) was stimulated by treating Jurkat cells with phorbol-12-myristate-13acetate (PMA) and phytohemaglutinin (PHA) (20) for 3 h.
Human WG2215 HCS-deficient skin fibroblast (Montreal Children’s Hospital Cell
Repository, Montreal, Canada) were cultured in Dulbecco’s modified Eagle’s medium
containing 10 nmol/l biotin to investigate effects of HCS deficiency on histone
biotinylation (19); human HCS wild-type IMR-90 fibroblasts (ATCC, Manassas, VA)
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were used as controls. HCS activity in IMR-90 and WG2215 fibroblasts was assessed by
using biotinylated carboxylases as markers in streptavidin blots (19).

Antibodies:

Rabbit anti-human H4K16bio was generated as described (6). Briefly, an H4-based,
K16-biotinylated synthetic peptide (GGAK(bio)RHRKVLRD, Anaspec; San Jose,CA)
was conjugated to keyhole limpet hemocyanin (KLH; Pierce, IL) and used as antigen for
injection into New Zealand rabbits. Specificity tests revealed that the anti-serum crossreacted

with

K16-acetylated

histone

H4,

using

the

synthetic

peptide

GGAK(ac)RHRKVLRD (H4K16ac) as a target (data not shown). To eliminate crossreactivity with H4K16ac, the antiserum was affinity purified by using immobilized
peptide H4K16ac and HiTrap™ NHS-Activated Sepharose™ High Performance Column
(cat.# 17-0717-01, GE Healthcare; Piscataway, NJ) following the manufacturer’s
protocol. Identity and purity of all synthetic peptides were confirmed by mass
spectrometry and HPLC, respectively, by the manufacturer.
Biotinylation site specificity of anti-H4K16bio was confirmed by using synthetic
histone-based peptides, histone bulk extracts, biotin-depleted histones, and competition
studies as described before (6). Equal loading and transfer was confirmed by staining
membranes with Ponceau S (19).
Polyclonal rabbit anti-human antibodies to H4K16bio, H4K12bio and H3K9me2
were generated in a commercial facility (Cocalico Biologicals, Reamstown PA) as
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described (6, 10, 19), while antibodies to the C-terminus in histone H3 (ab1791) and
H3K9ac (ab10812) were purchased from Abcam (Cambridge, MA). H3K9me2 and
H4K12bio were used as gene repression and heterochromatin marks, whereas H3K9ac
was used as a euchromatin mark. Rabbit polyclonal anti-human pyruvate carboxylase
(PC) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and PC in
transblots was probed as described before (19).

Micro chromatin immunoprecipitation (µChIP) assay:

The enrichment of H4K16bio in distinct loci in human chromatin was assessed by
micro chromatin immunoprecipitation (µChIP) assay as described (19, 23) with the
following modifications. Chromatin form Jurkat cells was precipitated using 14µl of antiH4K12bio and anti-H3K9me2, and 28 µl of anti-H4K16bio sera.

Quantitative real-time PCR (qRT-PCR):

The abundance of DNA in immunoprecipitated chromatin was quantified by qRTPCR using Perfecta SYBR Green FastMix ROX (VWR; West Chester, PA) and PCR
primers for long terminal repeats (LTR) 15 and 22, pericentromeric alpha satellite repeats
in chromosome 4, and promoters in genes coding for IL-2, sodium-dependent
multivitamin

transporter

(SMVT),

aldehyde

dehydrogenase

(ADH)

5,

and

glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (19). Amplicons were quantified
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using the cycle threshold values method (24). GAPDH was used to normalize qRT-PCR
data for amplification efficiency. The relative enrichment of histone marks in precipitated
chromatin was calculated as percent of input DNA (25, 26); enrichment data were
normalized for nucleosomal occupancy by precipitating samples with an antibody to the
(non-modified) C-terminus in histone H3. Non-specific rabbit IgG (Santa Cruz, Santa
Cruz, CA) was used as a control for background noise and precipitated negligible
amounts of chromatin (<5% of compared with anti-H4K16bio), consistent with previous
observations (19).
The abundance of mRNA coding for IL-2, LTR22, and SMVT was quantified using
Absolute QPCR SYBR Green fluorescein mix (ABgene; Rochester, NY) as described (6,
19).

Statistical analysis:
Bartlett’s test was used to test for homogeneity of variances (27). Data were log
transformed if variances were heterogeneous. Significance of differences among more
than two groups was tested by one-way ANOVA and Fisher’s Protected Least Significant
Difference procedure for post hoc testing. Student’s paired t-test was used for pairwise
comparisons of data from Jurkat cells before and after stimulation with PMA and PHA.
µChIP data from WG2215 and IMR-90 fibroblasts were not normally distributed and
were analyzed by using the Mann-Whitney U test. StatView 5.0.1 (SAS Institute, Cary
NC, USA) was used to perform all calculations. Differences were considered statistically
significant if P < 0.05. Data are expressed as mean ± S.D.
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Results
Specificity of anti-H4K16bio:
Affinity-purified anti-H4K16bio is specific for its designated target, based on the
following lines of observations. In a first series of experiments we compared the affinity
of anti-H4K16bio for the synthetic peptides H4K16bio and H4K16ac (Fig. 1A). Purified
anti-H4K16bio produced a strong signal with peptide H4K16bio (lane 1), but not signal
with peptide H4K16ac (lane 2). The presence of biotinylation and acetylation marks was
confirmed by probing transblots with IRDye-streptavidin (lanes 3 and 4) and antiH4K16ac (lanes 5 and 6). Equal loading and transfer was confirmed by staining
transblots with Ponceau S (lanes 7and 8). Note the non-specific signal in the Ponceau Sstained membrane, caused by interference of the dye in the sample loading buffer
(denoted “L”).
In a second series of experiments, we assessed the biotinylation site specificity of
anti-H4K16bio by comparing its binding to synthetic peptides biotinylated at K8 (N615bioK8),

K12 (N6-15bioK12), or K16 (N13-24bioK16), where subscripts denoted amino

acid residues in histone H4; the non-biotinylated peptide N1-19 was used as negative
control. Anti-H4K16bio produced a strong signal with peptide H4K16bio, whereas the
signals with peptides H4K8bio and H4K12bio were hardly detectable (Fig. 1B, lanes 13); no signal was detectable with non-biotinylated peptide (lane 4). Equal biotinylation of
synthetic peptides was confirmed by probing transblots with IRDye-streptavidin (Fig. 1C,
lanes 1-3); equal loading of the non-biotinylated peptide N1-19 was confirmed
gravimetrically.
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Figure 1. Validation of anti-H4K16bio. (A) K16-biotinylated and –acetylated peptides
were probed with anti-H4K16bio, IRDye-streptavidin, anti-H4K16ac, and Ponceau S. (B)
Synthetic H4-based peptides biotinylated at K8 (N6-15bioK8), K12 (N6-15bioK12), and
K16 (N13-24bioK16), and non-biotinylated peptide N1-19 were probed with anti-H4K16bio.
(C) Peptides H4K8bio, H4K12bio, and H4K16bio from panel B were probed with
IRDye-streptavidin. (D) Bulk extracts of Jurkat cell histones were probed with IRDyestreptavidin, anti-H4K16bio and pre-immune serum; “-“ denotes biotin-depleted histone
samples. (E) Bulk extracts of Jurkat cell histones were probed with anti-H4K16bio in the
presence of increasing amounts of synthetic peptides H4K16bio, H4K12bio, and
H4K8bio. The control sample (“C”) was assayed in the absence of peptide competitors.
Some gels were electronically re-arranged to facilitate comparisons. Abbreviations: L,
loading buffer; P, peptide.
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In a third series of experiments, we identified H4K16bio in histone bulk extracts
from Jurkat cells. First, we probed histones with streptavidin to demonstrate that the
majority of biotinylation marks resides in histones H3 and H4, and that biotinylation of
histones H1, H2A, and H2B is quanitatively minor (Fig. 1D, lane 1), consistent with our
previous results (4). Equal loading and integrity of proteins was confirmed by staining
with Commassie blue (not shown). When histones were probed with anti-H4K16bio the
antibody produced a signal only with histone H4, but not with other classes of histones
(lane 2). This signal was specifically caused by the biotinylated fraction of histone H4,
because biotin-depleted histones did not produce a signal (lane 3). When transblots were
probed with pre-immune serum, no signal was detectable (lane 4).
In a fourth and final series of antibody testing, bulk extracts of Jurkat cell histones
were probed with anti-H4K16bio in the presence of increasing amounts of synthetic
peptides. As expected, peptide H4K16bio outcompeted histone H4 for binding by antiH4K16bio compared with peptide-free control (Fig. 1E, lanes 1-5). In contrast, peptides
H4K12bio (lanes 6-9) and H4K8bio (lanes 10-13) did not compete for binding.

Relative enrichment of H4K16bio at selected genomic loci:

H4K16bio

is

overrepresented

in

pericentromeric

alpha

satellite

repeats

(heterochromatin) in chromosome 4 compared the promoters of the two euchromatin
genes GAPDH and ADH5 in Jurkat cells (Fig. 2A); the enrichment of H4K16bio in the
promoters of the two euchromatin genes GAPDH and ADH5 produced comparable
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signals. The known repression marks H4K12bio and H3K9me2 (18, 19) were used as
positive controls and showed a pattern similar to that of H4K16bio (Fig. 2B and C). In
contrast, the known activation mark H3K9ac (negative control) was greatly enriched in
euchromatin promoters compared with pericentromeric alpha satellite repeats (Fig. 2D).

Figure 2. H4K16bio is overrepresented in pericentromeric alpha satellite repeats
(heterochromatin) compared with promoters in euchromatin. Chromatin was
immunoprecipitated using antibodies to H4K16bio, H4K12bio, H3K9me2, and H3K9ac,
and qRT-PCR was used to quantify the relative enrichment of alpha satellite repeats in
chromosome 4 (Chr4alpha), and promoters of the GAPDH and ADH5 genes. Bars
without a common letter are significantly different (n = 4, P < 0.05)
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H4K16bio was overrepresented in the transcriptionally repressed promoter in the IL2 gene prior to stimulation with PMA and PHA compared with 3 h after activation with
PMA and PHA (Fig. 3A). qRT-PCR was used to confirm efficacy
of de-repression of the IL-2 gene by treatment with PMA and PHA (arbitrary units): 1.0 ±
0.2 before stimulation vs. 28 ± 2.7 after stimulation (n=4; P < 0.05). The controls showed
the expected pattern. While the repression marks H4K12bio and H3K9me2 were
removed from the IL-2 gene promoter in response to stimulation with PMA and PHA
(Fig. 3B and C), the relative enrichment of the activation mark H3K9ac was greater after
than before gene activation (Fig. 3D).
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Figure 3. Differential enrichment of histone marks in the IL-2 gene promoter in
Jurkat cells. Jurkat cells were stimulated with PMA/PHA for 3h. Chromatin was
immunoprecipitated with antibodies to H4K16bio, H4K12bio, H3K9me2, and H3K9ac
before and after stimulation with phorbol-12-myristate-13-acetate (PMA) and
phytohemagglutinin (PHA). qRT-PCR was used to quantify the relative enrichment of IL2 promoter sequences. Bars without a common letter are significantly different (n = 5, P
< 0.05)

Biotin dependence:

Previous studies suggest that the abundance of H3K9bio, H3K18bio, H4K8bio, and
H4K12bio at LTR15, LTR22, and SMVT promoter 1 depends on the concentration of
biotin in culture media and dietary biotin intake in various model organisms including
healthy adults (14, 15, 19). Here, we observed a similar scenario for H4K16bio. The
H4K16bio mark was 13-fold and 4-fold more abundant in the LTR22 locus in cells
cultured in medium containing 10 nmol/l compared with cells cultured in 0.025 nmol/l,
and 0.25 nmol/l biotin, respectively (Fig. 4A). Similar patterns were observed for the
repression marks H4K12bio (Fig. 4B), and H3K9me2 (Fig.4C), while the enrichment of
H3K9ac was not affected by biotin (Fig. 4D). Consistent with previous observations (14),
biotin deficiency (i.e., low abundance of H4K16bio at LTRs) de-repressed
retrotransposons. The abundance of LTR transcripts originating in the U5 region (14) was
2.9 ± 0.6 in cells cultured in medium containing 0.025 nmol/l, 0.9 ± 0.06 in cells cultured
in medium containing 0.25 nmol/l, and 0.2 ± 0.02 in cells cultured in medium containing
10 nmol/l (arbitrary units, n=4, P < 0.05 among all treatment groups).
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Figure 4. The abundance of H4K16bio at the LTR22 locus depends on the
concentration of biotin in culture media. Cells were cultured in biotin-defined media
for 12 d, and chromatin was precipitated with antibodies to H4K16bio, H4K12bio,
H3K9me2, and H3K9ac; qRT-PCR was used to quantify the relative enrichment of
LTR22 sequences. Bars without a common letter are significantly different (n = 4-5, P <
0.05).

The enrichment of H4K16bio, H4K12bio, and H3K9me2 at the SMVT promoter 1
locus was comparable to that at LTR22, e.g., the H4K16bio mark was 1.7-fold and 1.4fold more abundant in cells cultured in medium containing 10 nmol/l compared with cells
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cultured in 0.025 nmol/l, and 0.25 nmol/l biotin, respectively. However, the differences
among the different biotin concentrations did not reach statistical significance for the
SMVT promoter (P = 0.21).
The efficacy of biotin treatment was confirmed by probing biotinylated
holocarboxylases with IRDye-streptavidin (Fig. 5, upper gel). Clearly, the abundance of
holocarboxylases depended on the concentration of biotin in culture media. Equal loading
of lanes was confirmed by using anti-PC as a probe for total PC (holo & apo; Fig. 5,
lower gel).

Figure 5. Biotinylation of carboxylases depends on the concentration of biotin in
culture media. Jurkat cells were culture in biotin-defined media for 12 d, and
carboxylase-bound biotin was probed with IRDye-streptavidin in pyruvate carboxylase
(PC), 3-methylcrotonyl-CoA carboxylase (MCC), and propionyl-CoA carboxylase (PCC)
(upper gel). Equal loading of lanes was confirmed by using anti-PC as a probe (lower
gel).
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HCS deficiency:

Consistent with a previous report (19), the enrichment of H4K16bio and the
repression marks H4K12bio and H3K9me2 decreased at the LTR22 locus in HCSdeficient fibroblasts (WG2215) compared with HCS-normal fibroblasts (IMR-90) (Fig. 6.
A-C). The same pattern was obtained if H4K16bio was studied at SMVT promoter 1 and
LTR15 loci (data not shown). HCS activity in both types of fibroblasts was confirmed by
probing transblots of biotinylated carboxylases with IRDye-streptavidin (Fig. 6D, upper
gel). Biotinylated carboxylases were easily detectable in IMR-90 fibroblasts, whereas no
signal was detectable in WG2215 fibroblasts. Anti-PC was used to confirm that the
decrease of biotinylation signal in WG2215 cells was due to the inability of mutant HCS
to biotinylate carboxylases rather than low apocarboxylases expression or differences in
the loading or integrity of the proteins (Fig. 6D, lower gel).
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Figure 6. The enrichment of H4K16bio at LTR22 depends on HCS in primary
fibroblasts. (A-C) HCS-normal fibroblasts (IMR-90) and HCS-deficient fibroblasts
(WG2215) were cultured in medium containing 10 nmol/l biotin. Chromatin was
precipitated with antibodies to H4K16bio, H4K12bio, and H3K9me2, and qRT-PCR was
used to quantify the relative enrichment of LTR22. Bars without a common letter are
significantly different (n = 3-4, P < 0.05). (D) Biotin in PC, MCC, and PCC was probed
with IRDye-streptavidin (upper gel); equal loading was confirmed by using anti-PC as a
probe (lower gel).
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Discussion
Here, we demonstrate that K16 in human histone is a target for covalent
biotinylation, and we provide first insights into possible biological functions of
H4K16bio in pericentromeric heterochromatin and gene repression. A novel antibody
was generated and its specificity for H4K16bio was demonstrated in an extensive series
of testing. Importantly, we report that the abundance of the H4K16bio mark depends on
both biotin supply and HCS activity.
H4K16bio seems to play an important role in gene regulation, based on the following
observations. First, the enrichment of H4K16bio in the IL-2 gene promoter greatly
decreases in response to gene activation with phorbol ester and mitogen; H4K16bio
depletion co-incides with an increase in the abundance of IL-2 transcript. Second, the
enrichment of H4K16bio at the retroelement LTR22 depends on the concentration of
biotin in culture media; H4K16bio depletion co-incides with an increase in the abundance
of LTR transcript. This observation is particularly important given that previous in-depth
studies of retroelement repression suggest an increase in chromosomal abnormalities and,
therefore, cancer risk in biotin-depleted cells (14). Third, the enrichment of H4K16bio in
the SMVT gene promoter increases in response to biotin supplementation. In previous
studies we provided evidence that increased biotinylation of histones in the SMVT
promoter is an important regulatory mechanism to repress the expression of the SMVT
gene in biotin-supplemented cells (15). It appears that the roles of histone biotinylation in
gene repression are not specific for distinct biotinylation sites, as all biotinylation sites
studies to date are overrepresented in transcriptionally repressed chromatin (18, 19).
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A recent report suggests that some of the commercial antibodies to biotinylated
histones cross-react with acetylated histones (28). In response to that report, we reexamined our in-house antibodies to H3K9bio, H3K18bio, H4K8bio, and H4K12bio and
did not detect any cross-reactivity with acetylation marks {(13), T. Kuroishi et al., in
preparation}. We propose that these conflicting results are caused by the targets used for
specificity testing. Healy et al. used recombinant histones that were enzymatically
acetylated or biotinylated (28); the extent acetylation and biotinylation and the actual
modification sites (e.g., K8 vs. K12) remained unknown. In contrast, in our studies we
used synthetic peptides as targets, where both the extent and location of the modification
were unambiguous {(13), T. Kuroishi et al., in preparation}. However, in contrast with
the other in-house antibodies, the batch of polyclonal anti-H4K16bio tested here showed
some cross-reactivity with H4K16ac. It seems prudent to individually validate each batch
of polyclonal antibodies to biotinylated histones.
Our studies of histone biotinylation in HCS mutant fibroblasts lend further strength
to the notion that histone biotinylation is a real phenomenon. The abundance of
biotinylation marks was substantially lower in HCS mutant WG2215 fibroblasts
compared with IMR-90 fibroblasts. Similar observations were made in previous studies
(10, 14, 15), along with the observation that recombinant human HCS and its microbial
ortholog BirA biotinylate histones in vitro (11, 13). There is still some level of
uncertainty as to whether effects of HCS on gene regulation are mediated by biotinylation
of histones or biotinylation of proteins such as carboxylases. However, the phenotypes of
HCS knockdown are vastly different than phenotypes of carboxylase knockdown (7, 29),
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suggesting that aberrant biotinylation of histones in HCS-deficient cells impairs gene
regulation.
Two recent reports suggest that histone biotinylation is rare, occurring in <0.1% of
histones (16) or that biotinylation of histones might be an in vitro artifact (28). We agree
that histone biotinylation is rare, but stress that the abundance of any epigenetic mark
must not be confused with its importance. For example, only ~3% of cytosines are
methylated, but the role of DNA methylation in gene regulation is undisputed (30).
Likewise, phosphorylation of serine-14 in histone H2B and poly(ADP-ribosylation) of
histones are detectable only after induction of apoptosis and major DNA damage,
respectively, but the role of these epigenetic marks in cell death is clear (31-33).
Moreover, low abundance of an epigenetic mark in bulk histone extracts and high
enrichment at specific loci are not mutually exclusive. Evidence suggests that about one
out of three histone H4 molecules might be biotinylated at K12 in telomeric repeats (17).
We conclude that biotinylation of histones H3 and H4 plays important roles in gene
regulation and genome stability. Further mechanistic studies in whole organisms await
the arrival of a conditional HCS knockout mouse, which is an ongoing effort in our
laboratory.
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CHAPTER 3

A 96-WELL PLATE ASSAY FOR HIGH-THROUGHPUT
ANALYSIS OF HOLOCARBOXYLASE SYNTHETASE ACTIVITY
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Introduction
Holocarboxylase synthetase (HCS, E.C. 6.3.4.10) was identified by Suzuki and coworkers (1, 2); it catalyzes the covalent attachment of biotin to distinct lysine residues in
carboxylases (3). Mammalian cells express the following five carboxylases: acetyl-CoA
carboxylase 1 in the cytoplasm, and acetyl-CoA carboxylase 2, 3-methylcrotonyl-CoA
carboxylase, propionyl-CoA carboxylase, and 3-methyl-crotonyl-CoA carboxylase in
mitochondria. Biotinylated carboxylases play essential roles in the metabolism of fatty
acids, amino acids, and glucose (4, 5).
HCS also catalyzes the binding of biotin to lysines in histones (6). Histones H3 and
H4 are better targets for biotinylation than other histones (7, 8), but biotinylation sites
have been identified in H2A, H3, and H4 (9-11). Biotinylation of histones plays essential
roles in gene repression and genome stability (12-14).
Consistent with the important role for HCS as protein biotinyl ligase, the monomeric
enzyme is widely distributed throughout cells and has been detected in cytoplasm,
mitochondria, and nuclei in mammalian cells (1, 15, 16). Three splicing variants of HCS
have been identified in human placenta with molecular weights of 86, 82, and 76 kDa
(15, 17) but additional variants might exist (1). Nuclear HCS is a chromatin protein (18)
and appears to be enriched near the nuclear lamina (16).
To date, no living HCS null individual has been identified, suggesting embryonic
lethality. HCS knockdown studies (~30% residual activity) produced phenotypes such as
decreased life span and heat resistance (18) and increased frequency of retrotransposition

53
events in Drosophila melanogaster (13). Numerous mutations in the human HCS gene
have been identified and characterized at both the enzymatic and clinical level (19, 20).
Unless diagnosed and treated early, HCS deficiency appears to be uniformly fatal (21). In
most individuals clinical signs improve if treatment with pharmacological doses on biotin
is initiated early (19-22). In addition to mutations, about 2,200 single nucleotide
polymorphisms have been mapped in the HCS locus but their importance for human
health is unknown (23).
The prevention of adverse effects of HCS deficiency depends on the early diagnosis
of enzyme activity. As of today, analysis of HCS activity depends on indirect assays that
quantify the abundance of biotinylated carboxylases (“multiple carboxylase deficiency”).
These assays are cumbersome and do not lend themselves to the analysis of a large
number of samples, as required for studies of enzyme kinetics in HCS-deficient
individuals. Moreover, our laboratory is interested in the identification of synthetic and
natural HCS inhibitors that specifically target distinct subcellular structures. Such
inhibitors would provide useful tools to distinguish biological effects mediated by
biotinylation of cytoplasmic and mitochondrial carboxylases from those mediated by
biotinylation of nuclear histones. Here we took an important step towards these goals and
developed a 96-well assay for high-throughput analysis of both purified HCS and HCS in
biological samples.
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Materials and Methods
Principle of assay
The assay is based on the HCS-dependent biotinylation of a polypeptide named p67,
followed by detection and quantification of p67-bound biotin in a 96-well plate format
using IRDye-streptavidin and infrared spectroscopy. p67 comprises the 67 C-terminal
amino acids in human propionyl-CoA carboxylase, including the biotin-binding site
lysine-669, and is a widely accepted substrate in studies of HCS (24). Briefly, a mixture
(50 µl) of 75 mmol/l Tris-acetate (pH 8.0; all concentrations are final), 7.5 mmol/l ATP,
0.3 mmol/l dithiothreitol, 0.3 mmol/l biotin, 45 mmol/l MgCl2, 6 nmol/l recombinant
HCS (rHCS), and 8 µmol/l recombinant p67 was incubated for two hours at 37°C, unless
noted otherwise (“Results”). Recombinant proteins were stored for up to 6 months
without appreciable loss of activity; dithiothreitol and ATP were stored in small aliquots
at -20°C. Reactions were terminated by mixing 40 µl of sample with 60 µl of coating
buffer containing 50 mmol/l sodium carbonate (pH 9.6) and 200 mmol/l sodium EDTA in
black 96-well plates (Corning, New York, NY; catalog number 3601); plates were
incubated over night at 4°C on a rotating shaker. The coating buffer was removed, wells
were washed twice with distilled water, and blocked with 200 µl of blocking solution
{0.1% bovine serum albumin (wt./vol) and 0.05% Tween-20 (vol./vol) in phosphatebuffered saline} for at least 4 h at 4°C. The blocking solution was discarded, and plates
were washed twice with phosphate-buffered saline and incubated with 100 µl of
IRDye®-800CW-streptavidin for 1 h on a rotator at room temperature. IRDye-
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streptavidin was prepared by diluting a commercial stock solution (LI-COR, Lincoln,
NE; catalog number 926-32230; 2.4 moles of IRDye 800 CW/mole of streptavidin, 1
mg/ml) 4,000-fold in 0.1% Tween 20 in phosphate-buffered saline. Plates were washed
four times with 0.1%-Tween-20 in phosphate-buffered saline. IRDye fluoresence was
quantified using the 800CW channel in an infrared imaging system (Odyssey LI-COR;
Lincoln, NE). HCS- or p67-free samples were used as negative controls.

Recombinant HCS (rHCS)
A clone of human HCS fused to glutathione S-transferase, S·tag, and 6x his·tag was
expressed and purified as described (6) with the following modifications. Cells were
centrifuged at 4ºC (3,000 g for 30 minutes) and precipitated cells were resuspended in 15
ml of binding buffer {PBS, pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8
mM KH2PO4, pH 7.3)} with protease inhibitor cocktail (Sigma, St. Louis, MO). Samples
were sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) for 7 min with a 10-s
burst (30% amplitude) alternated with 20-s resting periods. The lysate was centrifuged at
10,000 g for 10 min at 4ºC. The supernatant was collected and rHCS fusion protein was
purified by using GSTrap FF columns on an AKTA protein purification system (GE
Health care; Piscataway, NJ). Protein purity was confirmed by gel electrophoresis and
staining with coomassie blue; bioactivity of rHCS was tested using gel electrophoresis
with recombinant p67 as substrate as described (6). p67-free and HCS-free mixes were
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used as negative controls. Protein concentration was determined using the bicinchoninic
acid method (Pierce, Rockford, IL).

Expression and purification of p67
Recombinant p67 was used as substrate for HCS activity assays. His-tagged p67 was
produced and purified using His Trap FF columns on an AKTA protein purification
system (GE Healthcare, Piscataway, NJ) as described (8); purity was confirmed by using
gel electrophoresis and staining with coomassie blue. The microbial HCS ortholog BirA
is known to biotinylate an appreciable fraction of recombinant p67 (8); hence, the
biotinylated fraction of recombinant p67 was removed using avidin columns as described
(8). Protein concentrations were determined using the bicinchoninic acid method.

Assay calibration

Assays were calibrated by preparing dilution series of up to 0.8 nmoles/l of IRDyestreptavidin in phosphate-buffered saline. One molecule of streptavidin can bind up to
four molecules of biotin (25), but the true extent of biotin binding in this assay is
unknown. Hence, the assay was calibrated by assuming that 2 molecules of biotin were
bound per molecule of streptavidin. Infrared absorbance of IRDye-streptavidin was
measured at 800 nm (channel 800CW) in the Odyssey imaging system. Non-linear
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regression analysis was used to calculate Km and Vmax of HCS for p67 (GraphPad Prism
5.00; La Jolla, CA).

Analysis of HCS in human cells

Whole cell extracts from 150 * 106 Jurkat human lymphoid cells were prepared
using 500 µl of cold lysis buffer in the presence of protease inhibitors (26). Cells were
sonicated on ice (Branson 250 Digital Sonifier, Danbury, CT) with a 5-s burst (30%
amplitude). Complete lysis was confirmed by visual inspection under a light microscope.
Debris was removed by centrifugation at 1,600 g at 4ºC for 5 min; the supernatant
contained 17.3 µg/µl total protein. Activity of endogenous HCS was quantified using the
plate assay by incubating 23 µl of supernatant (~400 µg protein) with cofactors and
recombinant p67 in a final volume of 50 µl for 2 h at 37°C. Negative controls were
prepared by omitting supernatant and by supernatants for 2 min at 99°C.

Statistical analysis

Bartlett’s test was used to test for homogeneity of variances (27). Significance of
differences among more than two groups was tested by one-way ANOVA and Fisher’s
Protected Least Significant Difference procedure for post hoc testing. Student’s paired ttest was used for pairwise comparisons. StatView 5.0.1 (SAS Institute, Cary NC, USA)
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was used to perform all calculations. Differences were considered statistically significant
if P < 0.05. Data are expressed as mean ± S.D.

Results

Recombinant HCS and p67
Purified rHCS produced a protein of the expected size (114.6 kDa due to tags) and
was >90% pure as judged by staining with coomassie blue (Fig. 1A, lane 1). Likewise,
his-tagged recombinant p67 produced a chemically pure protein of the expected size,
judged by staining with coomassie blue (Fig. 1A, lane 2). When rHCS was incubated
with p67 and cofactors, a strong biotinylation signal was detected in p67 using
streptavidin as probe (Fig. 1A, lane 3), consistent with the notion that rHCS was
bioactive. Importantly, we confirmed our previous observation that recombinant p67 is
biotinylated by BirA in E. coli (Fig. 1B, lane 1) and therefore requires affinity
purification before use. When recombinant p67 was purified by using avidin columns, the
vast majority of biotinylated p67 was removed (Fig. 1B, lane 2). For all assays described
below, we used biotin-depleted p67.
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Fig 1. Recombinant HCS and p67. (A) Recombinant HCS (lane 1) and p67 (lane 2)
were purified using affinity chromatography and stained with coomassie blue (CB); p67
was incubated with rHCS and co-factors, and biotin was probed with streptavidin (SA,
lane 3). (B) Biotinylation of recombinant p67 by microbial BirA was probed with
streptavidin before and after purification of p67 by avidin chromatography.

Temperature and time
The catalytic activity of rHCS depended on temperature and time. When various
amounts of rHCS were incubated with p67 and cofactors at either 4°C or 37°C, enzyme
activities were significantly higher at 37°C (Fig. 2); representative examples (2.2 nmol/l
and 5.8 nmol/l rHCS) are depicted. At 4°C, enzyme activities were just above

60
background noise. This is consistent with enzyme-mediated rather than non-enzymatic
catalysis. All subsequent experiments were conducted at 37°C.

Fig. 2. Temperature dependency of rHCS. Various amounts of rHCS were incubated
with p67 and cofactors at 4˚C and 37˚C. Enzyme activities were measured by infrared
spectroscopy. Bars without a common letter are significantly different for the same
concentration of rHCS (n=3, P < 0.05).

When various amounts of rHCS were incubated with p67 and cofactors for 1, 2, or 3
h, enzyme activities increased linearly for up to 2 h, but leveled off thereafter. For
example, enzyme activities (7.2 nmol/l rHCS) were 12.6 ± 2.2 of infrared absorbance
after 1 h, 28.8 ± 2.9 after 2 h, and 34.1 ± 2.2 after 3 h (Fig. 3). Values are expressed in
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arbitrary units of infrared absorbance (800 nm) until assay optimization and calibration
was achieved (see below). All subsequent experiments were conducted using 2-h
incubations.

Fig. 3. Effect of incubation time on rHCS activity. rHCS was incubated with p67 and
cofactors for 1, 2 or 3 h at 37°C. Enzyme activity was measured by infrared spectroscopy.
Bars without a common letter are significantly different (n = 3, P < 0.05)

Concentrations of HCS and p67
The amount of p67 that was biotinylated in plate assays increased linearly up to a
concentration of rHCS of 8 nmol/l, and leveled off thereafter (Fig. 4). Subsequent
experiments were conducted using 6 nmol/l HCS to ensure assay linearity. Furthermore,
an rHCS dilution series was conducted to determine detection limit of rHCS in this assay.
At a concentration of 1.08 nmol/l HCS, biotinylation of p67 was significantly greater
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than in negative controls without rHCS (n = 3, P < 0.05), whereas 0.54 nmol/l HCS were
not significantly different from background controls (data not shown).

Fig. 4. rHCS concentration. Recombinant p67 was incubated with various
concentrations of rHCS and cofactors at 37°C for 2 h. Biotinylation of p67 was quantified
by IRDye-streptavidin and infrared absorbance.

Dose-response studies were conducted with varying amounts of p67 to determine a
concentration where substrate availability is no longer a limiting factor in this plate assay.
A linear dose-response was obtained for up to 5.2 µmol/l p67, while p67 was no longer
rate limiting beyond that concentration (Fig. 5). These findings were further corroborated
by enzyme kinetics studies. The apparent Km of rHCS for p67 equaled 4.1 ± 1.5 µmol/l
and the apparent Vmax equaled 34.9 ± 4.1 units of infrared absorbance (Fig.6). For
subsequent experiments, p67 was used at a concentration of 8 µmol/l.
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Fig. 5. p67 concentration. Various amounts of recombinant p67 were incubated with 6
nmol/l rHCS and cofactors at 37°C for 2 h. Biotinylation of p67 was quantified by
IRDye-streptavidin and infrared absorbance.

Fig 6. Kinetics of p67 biotinylation by rHCS. The line was fitted to the MichaelisMenten equation by nonlinear regression analysis (n = 3).
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Assay calibration
A dilution series of IRDye-streptavidin was prepared to calibrate the HCS assay. One
molecule of streptavidin can bind up to four biotin molecules (25); we assumed that each
molecule of IRDye-streptavidin bound, on average, two molecules of biotin under the
conditions of this assay. The dilution series of IRDye-streptavidin produced a linear
response across all concentrations tested (Fig. 7), and the assay system was re-calibrated
daily. A typical sample of rHCS under the conditions described in the preceding sections
produced a signal of about 36 units of infrared absorbance, suggesting that 0.16 µmol of
p67 were biotinylated when incubated with 6 nmol/l HCS for 2 h at 37°C. We define one
unit of HCS activity as 0.08 µmol of biotinylated p67 formed x nmol/l-1 HCS x h-1 at
37°C.

Fig. 7. Assay calibration. A standard curve was produced by quantifying the infrared
absorbance of IRDye-streptavidin (up to 0.8 nmol/well) at 800 nm. Note that 0.8 nmoles
of IRDye-streptavidin were considered to be the equivalent of 1.6 nmol of biotin/well (n
= 3).
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HCS activity in Jurkat cells

Supernatants from Jurkat cells contained 0.14 ± 0.02 µmol of biotinylated p67
produced per hour in 400 µg of total protein; no signal was detected in cell-free controls
and heat-treated protein extracts (negative controls).

Discussion
Here, we present a 96-well plate assay for high-throughput screening of HCS activity
based on the detection of biotinylated p67 using IRDye-streptavidin and infrared
absorbance. Previous assays of HCS activity are based on the biotinylation of p67 in a gel
electrophoresis-based format. While we acknowledge that the gel-based assay is slightly
more sensitive than the plate assay (not shown), we also note that the plate assay has the
advantages that large numbers of samples (including replicates) can be analyzed rapidly
and cost-efficiently. Despite its lower sensitive, analysis of HCS in cell extracts by plate
assay is feasible, as evidenced by successful quantification of enzyme activity in Jurkat
cell extracts. Moreover, the plate assay does not require the use of radiochemicals, unlike
some of the other assays of HCS deficiencies in patients with multiple carboxylase
deficiency (19). We envision two possible applications for the plate assay. First, the assay
can be used in the analysis of enzyme kinetics for mutant or variant human HCS,
including newborn screening. Second, the assay could be particularly useful when
screening libraries of synthetic or naturally occurring compounds for potential HCS
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inhibitors in a high-throughput format. With the newly discovered HCS-dependent
biotinylation of histones and its role in gene regulation and genome stability (12-14, 28),
the need for robust HCS assays can only increase.
This study confirmed our previous observations that particular attention needs to be
paid to the protocols for preparing recombinant p67 and HCS. Recombinant p67 contains
biotin and requires affinity purification prior to use in HCS assays (8), otherwise
artificially high activities may be recorded. The yield of bioactive rHCS is low, if
produced following protocols published in the 1990s, at least in our laboratory. We
suspect that the low yield of bioactive rHCS by previous protocols is caused by improper
folding of the protein and devised a protocol tailored towards maximizing the yield of
rHCS (6).
One obstacle to the broad use of this 96-well plate assay is its apparent dependence
on the availability of an infrared spectrophotometer, which may not be available in
clinical laboratories. If no infrared spectrophotometer is available, we propose modifying
the assay by substituting streptavidin-peroxidase for IRDye-streptavidin in a standard
plate reader format at 450 nm. We conclude that a robust method was developed for a
robust assay of HCS activities in both clinical and research settings.

67
References
1.
Chiba Y, Suzuki Y, Aoki Y, Ishida Y, Narisawa K. Purification and properties of
bovine liver holocarboxylase synthetase. Arch Biochem Biophys. 1994;313(1):8-14.
2.
Suzuki Y, Aoki Y, Ishida Y, Chiba Y, Iwamatsu A, Kishino T, et al. Isolation and
characterization of mutations in the human holocarboxylase synthetase cDNA. Nat
Genet. 1994;8(2):122-8.
3.
Dakshinamurti K, Chauhan J. Biotin-binding proteins. In: Dakshinamurti K,
editor. Vitamin Receptors: Vitamins as Ligands in Cell Communication. Cambridge, UK:
Cambridge University Press; 1994. p. 200-49.
4.
Knowles JR. The mechanism of biotin-dependent enzymes. Ann Rev Biochem.
1989;58:195-221.
5.
Kim K-H, McCormick DB, Bier DM, Goodridge AG. Regulation of mammalian
acetyl-coenzyme A carboxylase. Ann Rev Nutr. 1997;17:77-99.
6.
Bao B, Pestinger V, I. HY, Borgstahl GEO, Kolar C, Zempleni J.
Holocarboxylase synthetase is a chromatin protein and interacts directly with histone H3
to mediate biotinylation of K9 and K18. J Nutr Biochem. 2010;(in press).
7.
Stanley JS, Griffin JB, Zempleni J. Biotinylation of histones in human cells:
effects of cell proliferation. Eur J Biochem. 2001;268:5424-9.
8.
Kobza K, Sarath G, Zempleni J. Prokaryotic BirA ligase biotinylates K4, K9, K18
and K23 in histone H3. BMB Reports. 2008;41:310-5.
9.
Camporeale G, Shubert EE, Sarath G, Cerny R, Zempleni J. K8 and K12 are
biotinylated in human histone H4. Eur J Biochem. 2004;271:2257-63.
10.
Kobza K, Camporeale G, Rueckert B, Kueh A, Griffin JB, Sarath G, et al. K4,
K9, and K18 in human histone H3 are targets for biotinylation by biotinidase. FEBS J.
2005;272:4249-59.
11.
Chew YC, Camporeale G, Kothapalli N, Sarath G, Zempleni J. Lysine residues in
N- and C-terminal regions of human histone H2A are targets for biotinylation by
biotinidase. J Nutr Biochem. 2006;17(4):225-33.
12.
Camporeale G, Oommen AM, Griffin JB, Sarath G, Zempleni J. K12-biotinylated
histone H4 marks heterochromatin in human lymphoblastoma cells. J Nutr Biochem.
2007;18:760-8.
13.
Chew YC, West JT, Kratzer SJ, Ilvarsonn AM, Eissenberg JC, Dave BJ, et al.
Biotinylation of histones represses transposable elements in human and mouse cells and
cell lines, and in Drosophila melanogaster. J Nutr. 2008;138:2316-22.
14.
Pestinger V, Wijeratne SSK, Rodriguez-Melendez R, Zempleni J. Novel histone
biotinylation marks are enriched in repeat regions and participate in repression of
transcriptionally competent genes. J Nutr Biochem. 2010;(in press).
15.
Hiratsuka M, Sakamoto O, Li X, Suzuki Y, Aoki Y, Narisawa K. Identification of
holocarboxylase synthetase (HCS) proteins in human placenta. Biochim Biophys Acta.
1998;1385(1):165-71.

68
16.
Narang MA, Dumas R, Ayer LM, Gravel RA. Reduced histone biotinylation in
multiple carboxylase deficiency patients: a nuclear role for holocarboxylase synthetase.
Hum Mol Genet. 2004;13:15-23.
17.
Yang X, Aoki Y, Li X, Sakamoto O, Hiratsuka M, Kure S, et al. Structure of
human holocarboxylase synthetase gene and mutation spectrum of holocarboxylase
synthetase deficiency. Hum Genet. 2001;109(5):526-34.
18.
Camporeale G, Giordano E, Rendina R, Zempleni J, Eissenberg JC. Drosophila
holocarboxylase synthetase is a chromosomal protein required for normal histone
biotinylation, gene transcription patterns, lifespan and heat tolerance. J Nutr.
2006;136(11):2735-42.
19.
Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the
holocarboxylase synthetase gene HLCS. Human Mutation. 2005;26(4):285-90.
20.
Online Mendelian Inheritance in Man [database on the Internet]. National, Center
for Biotechnology Information. 2008 [cited 7/18/2008]. Available from:
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim.
21.
Thuy LP, Belmont J, Nyhan WL. Prenatal diagnosis and treatment of
holocarboxylase synthetase deficiency. Prenat Diagn. 1999;19(2):108-12.
22.
Wolf B. Disorders of Biotin Metabolism. In: Scriver CR, Beaudet AL, Sly WS,
Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York,
NY: McGraw-Hill; 2001. p. 3935-62.
23.
Entrez SNP [database on the Internet]. National Institutes for Health. 2008 [cited
11/28/2008]. Available from: http://www.ncbi.nlm.nih.gov.
24.
Leon-Del-Rio A, Gravel RA. Sequence requirements for the biotinylation of
carboxyl-terminal fragments of human propionyl-CoA carboxylase alpha subunit
expressed in Escherichia coli. Journal of Biological Chemistry. 1994;269(37):22964-8.
25.
Green NM. Avidin. Adv Protein Chem. 1975;29:85-133.
26.
Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. c-Myc target gene
specificity is determined by a post-DNA binding mechanism. Proc Natl Acad Sci U S A.
1998;95(23):13887-92.
27.
Institute S. StatView Reference. 3rd ed. Cary, NC: SAS Publishing; 1999.
28.
Gralla M, Camporeale G, Zempleni J. Holocarboxylase synthetase regulates
expression of biotin transporters by chromatin remodeling events at the SMVT locus. J
Nutr Biochem. 2008;19:400-8.

